Abstract
The objective of the present study is focused to elucidate the structure of potential anti-Alzheimer's compound 5,6-Dimethoxy-1-indanone (5,6-DMI) and study its binding interaction towards the active site by molecular docking studies. The structural and various spectroscopic tools are used to understand the various interaction behaviors of the title compound. The theoretical calculation of 5,6-DMI molecule is computed by Gaussian 09W software with Density functional B3LYP and CAM-B3LYP method utilizing 6-311G(d,p) as basis set. The Natural Bond Orbital (NBO) analysis has been performed to find all possible transition was correlate with electronic transition. The Non covalent interaction of 5,6-DMI molecule was examined by adopt Reduced Density Gradient (RDG) analysis and colour filled ELF diagram. Molecular docking results suggest that 5,6-DMI may exhibit inhibitory activity against apoE protein and may act as potential against Alzheimer's disease.
Highlights
Alzheimer's disease (AD) is a social threat and progressive neurodegenerative disorder and one of the most universal causes of mental weakening in the early age of human being
The study of different conformations of 5,6-DMI molecule based on its energy difference, the Conformer 1 is the most stable conformer which implies that the orientation of OCH3 is orient opposite plane will provide the least stable conformer is well coincide with already reported molecular structure 5,6-DMI by Shoja et al [12] and the results are once again confirmed by Potential Energy Surface scan study in the following discussion
From Potential Energy Surface (PES) scan study the energy change related to rotation of OCH3 group denote, both OCH3 group orient in opposite plane correlate with C1 conformer
Summary
Alzheimer's disease (AD) is a social threat and progressive neurodegenerative disorder and one of the most universal causes of mental weakening in the early age of human being. Recent research efforts are to study the drug development, determination of molecular, biochemical and cellular mechanisms of AD. The Acetyl Cholinesterase (AChE) inhibitors are being major and large amount developed class of drugs approved for AD therapy have been approved by Food and Administration (FDA) and European Medicines Evaluation Agency (EMEA) example such as donepezil, rivastigime and galanthamine for symptomatic treatment of behavioural and psychiatric symptoms of AD [1]. The indanone derivatives play an important part in the discovering of novel structural moiety for the action of AChE inhibitors [2]. The indanone derivative are seems to be interesting chemical used to synthesis some important biomedical applications oriented compound such as anticonvulsants [3] anticholinergics [4] and aromatic retinoids [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
